#United States #San Mateo #Helix #Alnylam #GenoSphere

Helix Enters Multi-Year Partnership with Alnylam

In a significant move for precision medicine, Helix, a leading enterprise genomics company, has declared a multi-year collaboration with Alnylam Pharmaceuticals, recognized as a frontrunner in RNAi therapeutics. This agreement aims to harness Helix's extensive genomic resources to propel innovation in the development of RNAi treatments that can address various diseases.

Founded on the principles of transforming healthcare through genomics, Helix provides access to its expansive and continuously growing repository known as the GenoSphere™. This unique platform contains deeply phenotyped cohorts that assertively cover myriad disease areas. Alnylam will benefit from tapping into Helix’s sophisticated databases that marry Exome+ sequencing with rich longitudinal clinical data, enhanced by medical and pharmacy claims.

Paul Nioi, Senior Vice President of Research at Alnylam Pharmaceuticals, emphasized the importance of genomic insights in advancing their drug discovery initiatives. He stated, "We believe that access to the Helix platform will bolster our efforts to identify new targets for RNAi therapeutics, an innovative class of medicines that silence genes linked to diseases." Using human genetics as their compass, Alnylam aims to ensure precision and effectiveness in their drug development processes with this new access to Helix's data.

The deep insights provided by Helix’s Exome+ sequencing are expected to cover thousands of genes and variants, offering crucial information into a broad spectrum of disease areas. Additionally, the curated clinical data, which has an impressive historical average of 13 years within electronic health records, captures essential patient health journeys, including diagnoses and lab results.

One of the impressive features of this agreement is that the dataset is fully consented, enabling Helix and Alnylam to conduct follow-up studies swiftly and accurately. This capability can significantly accelerate the innovation cycle within precision medicine, enhancing the ability to develop tailored therapeutics for diverse patient populations.

Helix’s CEO, Dr. James Lu, expressed optimism about the partnership. He noted, "This collaboration not only highlights the unparalleled scale and depth of our platform but also reinforces Helix's role as a global catalyst in advancing precision medicine. Our partnership with Alnylam aims to improve patient outcomes across major therapeutic areas, which is at the core of our mission."

Due to the size and scope of the Helix Research Network, which stands as the largest precision health network globally, the partnership has the potential to transform the landscape of genomic discoveries into actionable clinical results. Alnylam is set to leverage this vast pool of integrated data to advance their project aims effectively.

For more information about this strategic collaboration and to explore partnership opportunities, interested parties are encouraged to visit Helix's official website. This partnership will be a notable chapter in the ongoing narrative of precision medicine, as it aims to enhance the efficacy of RNAi therapeutics coming into the market.

As Helix and Alnylam embark on this journey together, the implications for patients and the healthcare system as a whole are significant. By combining cutting-edge genomic technology with robust research initiatives, both companies set the stage for pioneering breakthroughs in medical treatment, making strides towards curing diseases that have long challenged the medical field.